What is NovaBridge Biosciences (NBP) stock price today?

NovaBridge Biosciences (NBP) currently trades at $2.35 per share. The stock has a market capitalization of $271.77M and a P/E ratio of —x.

Is NBP stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, NovaBridge Biosciences has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 1.50.

Is NovaBridge Biosciences financially healthy?

NovaBridge Biosciences's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 1.50 places it in the distress.

NBP

NovaBridge Biosciences

NASDAQ: NBP · HEALTHCARE · BIOTECHNOLOGY

$2.35

-1.67% today

Updated 2026-04-29

Market cap

$271.77M

P/E ratio

—

P/S ratio

25.39x

EPS (TTM)

$-0.48

Dividend yield

—

52W range

$1 – $7

Volume

0.9M

Market cap

$271.77M

P/E ratio

—

P/S ratio

25.39x

EPS (TTM)

$-0.48

Dividend yield

—

52W range

$1 – $7

Volume

0.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.5

Quality

B+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

1.5

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$8.00

+240.43%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.09x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Altman Z 1.50 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-14.60M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$-10.70M	$4.49M	$0.00	$0.00	—
Net income	$-2.51B	$-1.47B	$-162.26M	$-46.27M	$11.07M
EPS	—	—	—	—	$-0.48
Free cash flow	$-1.15B	$-73.02M	$-52.70M	$-20.60M	$-14.60M
Profit margin	23,438.90%	-32,674.02%	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NBP	$271.77M	26	4.3	3.0	5.0	7.5	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

NovaBridge Biosciences trades at $2.35. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.50, it sits in the distress.

Frequently asked questions

What is NovaBridge Biosciences's stock price?

NovaBridge Biosciences (NBP) trades at $2.35.

Is NovaBridge Biosciences overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of NovaBridge Biosciences (NBP)?

The analyst target price is $8.00, representing +240.4% upside from the current price of $2.35.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

1.50 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryChina

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio25.39x

ROE-40.90%

Beta1.74

50D MA$2.80

200D MA$3.67

Shares out0.12B

Float0.15B

Short ratio—

Avg volume0.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NBP vs LLY →NBP vs JNJ →NBP vs ABBV →Stock screener →